OncoMatch/Clinical Trials/NCT06353360
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Is NCT06353360 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tumor Treating Fields and Tislelizumab for glioblastoma multiforme.
Treatment: Tumor Treating Fields · Tislelizumab · Temozolomide (TMZ) — The goal of this clinical trial is To investigate the safety and efficacy of Tumor-Treating Fields (TTFields) in combined with temozolomide (TMZ) and tislelizumab in the treatment of newly diagnosed glioblastoma (GBM).
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: IDH2 wild-type
Prior therapy
Must have received: surgical resection or biopsy
After brain surgery (patients with total resection, partial resection and biopsy were acceptable)
Must have received: concurrent chemoradiotherapy with temozolomide (temozolomide)
completed TMZ concurrent chemoradiotherapy were planned for adjuvant TMZ treatment
Cannot have received: cytotoxic or biologic antineoplastic therapy
The subject had received any other cytotoxic or biologic antineoplastic therapy before enrollment
Cannot have received: anti-PD-1 antibody
Previous treatment with anti-PD-1 antibody
Cannot have received: anti-PD-L1 antibody
Previous treatment with anti-PD-L1 antibody
Cannot have received: anti-CTLA-4 antibody
Previous treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody
Lab requirements
Blood counts
Thrombocytopenia (platelet count < 100×10^3/μL); Neutropenia (absolute neutrophil count < 1.5×10^3/μL)
Kidney function
Severe renal impairment (serum creatinine >1.7 mg/dL, or >150 μmol/L)
Liver function
Significant liver function impairment -aspartate aminotransferase (AST) or alanine transaminase (ALT) exceeding 3 times the upper limit of normal; Total bilirubin more than 1.5 times the upper limit of the normal range
Participants had to meet certain criteria for bone marrow, liver and kidney function before enrollment, and were not eligible if they had any of the following: Thrombocytopenia (platelet count < 100×10^3/μL); Neutropenia (absolute neutrophil count < 1.5×10^3/μL); Significant liver function impairment -aspartate aminotransferase (AST) or alanine transaminase (ALT) exceeding 3 times the upper limit of normal; Total bilirubin more than 1.5 times the upper limit of the normal range; Severe renal impairment (serum creatinine >1.7 mg/dL, or >150 μmol/L).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify